Denise Carter Purchases 20,490 Shares of Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) COO Denise Carter acquired 20,490 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The shares were bought at an average price of $4.88 per share, for a total transaction of $99,991.20. Following the transaction, the chief operating officer owned 37,709 shares of the company’s stock, valued at approximately $184,019.92. The trade was a 119.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Quoin Pharmaceuticals Stock Performance

QNRX stock opened at $6.74 on Thursday. The company’s fifty day moving average price is $4.83 and its 200-day moving average price is $5.88. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a one year low of $3.25 and a one year high of $41.80. The company has a market capitalization of $13.53 million, a PE ratio of -0.27 and a beta of 1.50.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its earnings results on Friday, August 14th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.61) by ($0.29). On average, research analysts predict that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. ThinkEquity assumed coverage on Quoin Pharmaceuticals in a report on Monday, June 15th. They set a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Institutional Trading of Quoin Pharmaceuticals

A number of large investors have recently made changes to their positions in QNRX. Simplify Asset Management Inc. purchased a new stake in shares of Quoin Pharmaceuticals during the 4th quarter valued at about $252,000. SummitTX Capital L.P. increased its stake in Quoin Pharmaceuticals by 54.8% during the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after acquiring an additional 35,505 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter valued at approximately $840,000. Boothbay Fund Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter valued at approximately $863,000. Finally, Millennium Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter valued at approximately $1,080,000. 8.63% of the stock is currently owned by institutional investors.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.